AnaptysBio, Inc.（ANAB）資訊與事件

$55.280

-1.697 (-3.07%)收盤時

ANAB 資訊

9.505-12seekingalpha

AnaptysBio Q1 Earnings Report Analysis

5.005-11Newsfilter

AnaptysBio Strengthens Leadership Team and Board

9.004-28PRnewswire

Vanda Pharmaceuticals Publishes Imsidolimab Research Findings

9.004-28Newsfilter

Vanda Pharmaceuticals Announces Imsidolimab Research Findings

7.004-27seekingalpha

Tesaro and AnaptysBio Litigation Update

7.004-27seekingalpha

Delaware Court Dismisses AnaptysBio's Claim Against TESARO

7.004-27moomoo

GSK and Tesaro Assert That Allegations Lack Merit and Are Committed to Defending Their Case in Court

8.504-20seekingalpha

AnaptysBio Completes Spinoff of First Tracks Biotherapeutics

8.504-20Newsfilter

AnaptysBio Completes Spin-Off, Focuses on Royalty Management

8.504-20moomoo

ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS

查看更多資訊

ANAB 事件

7/15 10:30

AnaptysBio Shares Drop 10.8% to $55.76

AnaptysBio is down -10.8%, or -$6.75 to $55.76.

5/12 16:50

Anaptys Reports Q1 Revenue of $25.56M, Exceeding Expectations

Reports Q1 revenue $25.56M, consensus $18.87M. "Following the completion of the spin-off of First Tracks Bio in late April, Anaptys now exclusively manages the financial collaborations for Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and delivering an EBIT margin greater than 95%," said Daniel Faga, president and chief executive officer. "With Chris Murphy joining as CFO, who brings deep business development and investment banking experience, our priority continues to be to protect our two royalty streams and return their value to shareholders."

5/11 09:40

AnaptysBio Appoints Christopher Murphy as CFO

AnaptysBio announced the appointment of Christopher Murphy as CFO and Owen Hughes as a member of its board of directors. Murphy previously served as CFO and CBO of Third Harmonic Bio.

4/27 06:40

GSK Subsidiary TESARO Wins Court Dismissal Against AnaptysBio

GSK (GSK) subsidiary, TESARO, confirms that the Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio (ANAB) against TESARO's claim for anticipatory breach. The court's ruling does not address the merits of the principal contractual dispute between the parties and has no impact on TESARO's remaining claim against AnaptysBio for declaratory judgment. GSK and TESARO are firmly of the view that these allegations are entirely without merit and remain focused on pursuing that claim at trial. TESARO initiated this litigation following allegations made by AnaptysBio that TESARO has not fulfilled certain requirements of the license agreement entered in March 2014 between the parties and that AnaptysBio intends to revoke TESARO's licence for dostarlimab.

4/24 15:50

AnaptysBio Court Dismisses Tesaro's Breach of Contract Claim

AnaptysBio (ANAB) announced that the Delaware Chancery Court has dismissed Tesaro's anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys' position that it has never repudiated the collaboration and exclusive license agreement with Tesaro, a subsidiary of GSK (GSK), governing the development and commercialization of Jemperli. As stated in Anaptys' original filing, the company's motion explained "why, as a matter of law, Anaptys has never repudiated the Collaboration Agreement and how Anaptys has only sought to vindicate its contract rights." The court's decision confirms that Tesaro's anticipatory breach of contract claim was insufficiently pleaded and rejects Tesaro's request for any royalty reduction. The trial is scheduled for July 14-17.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。